Loading clinical trials...
Loading clinical trials...
An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Conditions
Interventions
Eteplirsen
Locations
4
Belgium
Universitair ziekenhuis Gent
Ghent, Belgium
Armand-Trousseau Hospital
Paris, France
Site Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
UCL Great Ormond Street Institute of Child Health
London, United Kingdom
Start Date
August 16, 2017
Primary Completion Date
March 10, 2021
Completion Date
March 10, 2021
Last Updated
December 9, 2021
NCT07037862
NCT07160634
NCT06450639
NCT07129954
NCT06290713
NCT06925269
Lead Sponsor
Sarepta Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions